One-step CRISPR-Cas9 protocol for the generation of plug & play conditional knockouts in *Drosophila melanogaster*

This one-step method generates, for any locus, a conditional knockout allele in *Drosophila*. The allele carries a bright fluorescent marker for easy screening and an attP landing site for subsequent genetic manipulations. After removing the selectable marker with Cre, the attP site can be used to insert DNA fragments expressing tagged or mutant alleles to determine protein localization and function in a tissue- and stage-specific manner. Only a single round of CRISPR-Cas9-mediated editing is required.
Protocol

One-step CRISPR-Cas9 protocol for the generation of plug & play conditional knockouts in *Drosophila melanogaster*

Joyce J.S. Yu,1 Jean-Paul Vincent,1,2,3,* and Ian J. McGough1,*

1The Francis Crick Institute, London NW1 1AT, UK
2Technical contact
3Lead contact
*Correspondence: jp.vincent@crick.ac.uk (J.-P.V.), Ian.McGough@crick.ac.uk (I.J.M.)

https://doi.org/10.1016/j.xpro.2021.100560

SUMMARY

This one-step method generates, for any locus, a conditional knockout allele in *Drosophila*. The allele carries a bright fluorescent marker for easy screening and an attP landing site for subsequent genetic manipulations. After removing the selectable marker with Cre, the attP site can be used to insert DNA fragments expressing tagged or mutant alleles to determine protein localization and function in a tissue- and stage-specific manner. Only a single round of CRISPR-Cas9-mediated editing is required.

For complete details on the use and execution of this protocol, please refer to the *DWnt4[cKO]* example in Yu et al. (2020).

BEFORE YOU BEGIN

sgRNA selection

© Timing: 1 h

Select sgRNAs and order oligonucleotides for insertion of corresponding coding DNA into the pCFD4 vector (Addgene: 49411), which allows tandem gRNA expression (Port et al., 2014). Target sites should be chosen such that they direct Cas9 to the 5′ and 3′ ends of the genomic sequence to be deleted. In the example for *DWnt4* in Figure 1, these are located slightly upstream of the 5′ UTR and downstream of the 1st exon.

*Alternatives:* An alternative is the newer pCFD5 vector (Addgene: 73914), which allows the efficient expression of up to 6 sgRNAs (Port and Bullock, 2016).

1. Obtain the full genomic sequence of your gene of interest from FlyBase (https://flybase.org/) by searching the gene name and label all coding exons and UTRs.

   *Note:* Applications such as SerialCloner (http://serialbasics.free.fr/Serial_Cloner.html) or SnapGene (https://www.snapgene.com/) provide user-friendly means of displaying and annotating genomic sequences.

2. On the FlyBase page for the gene of interest, view the genomic sequence on the UCSC genome browser (http://genome-euro.ucsc.edu/) (Figure 1).
a. Identify and highlight a non-conserved region upstream of the region to be deleted (in this instance the 5'UTR and 1st exon of DWnt4 is to be deleted, and the chosen non-conserved region is approximately 500 base pairs upstream of the 5'UTR).
b. Identify and highlight a second non-conserved region downstream of the region to be deleted (in this instance the chosen non-conserved region is approximately 500 base pairs downstream of the 1st exon).

△ CRITICAL: The presence of residual sequences from FRT, attP or loxP sites could impair expression of your gene of interest if they are located in important (conserved) regulatory regions. Non-conserved areas are chosen to maximise the chance that reintegrated DNA is faithfully expressed.

3. For each non-conserved region from steps 2a-b, copy and paste the sequence into a CRISPR target finder tool such as http://targetfinder.flycrispr.neuro.brown.edu/. Select the “Drosophila melanogaster” genome and the guide length as 20nt. On the next page, select ‘High Stringency’, and ‘NGG only’ for PAM.

4. Select sgRNAs that have no predicted off-target sites.

△ CRITICAL: if off-target sites are unavoidable, choose sgRNAs with predicted off-target sites that are on a different chromosome from the gene of interest. This will allow unintended modifications to be more easily crossed out subsequently (see troubleshooting 1).

sgRNA primer design

△ Timing: 3 days

To ensure that no SNP is present in the chosen target sequences, which could prevent efficient DNA cleavage, the regions around the two chosen sgRNA target sites are sequenced from the genomic DNA obtained from the injection host strain (Figure 2A).
**Note:** For commonly used Cas9 lines, it is now possible to search for target sites within the sequenced Cas9 genomes, thus eliminating the need to perform step 5. Examples of these tools include [https://www.flyrnai.org/crispr3/](https://www.flyrnai.org/crispr3/) and [http://targetfinder.flycrispr.neuro.brown.edu/](http://targetfinder.flycrispr.neuro.brown.edu/). If not using such a sequenced Cas9 line proceed with step 5.

5. Design primers for PCR amplification of ~150bp on either side of the two chosen sgRNA target sites. PCR from genomic DNA obtained from injection host strain (Figure 2A).
   a. The host strain should bear a Cas9-expressing transgene on a different chromosome from that of the target locus. This allows for subsequent removal of the Cas9-expressing transgene and its associated markers. A list of available Cas9-expressing strains can be found in (Kondo and Ueda, 2013) and at websites such as, flyCRISPR website ([https://flycrispr.org/reagents/](https://flycrispr.org/reagents/)), and the CRISPR fly design website ([http://www.crisprflydesign.org/flies/](http://www.crisprflydesign.org/flies/)). Lines in which Cas9 is driven by germline promoters such as vasa-Cas9 or nanos-Cas9 should be used. This avoids somatic alteration, which could affect the survival or fitness of the organism. In the case of the DWnt4[cKO] example, yw;;nos-Cas9(III-attP2) from (Kondo and Ueda, 2013) was used.

   △ CRITICAL: In certain Cas9 lines, the Cas9-expressing transgene is marked with GFP, which would interfere with the screening via the pax-GFP marker later on. Avoid using such Cas9 lines.

   b. In preparation for extraction of genomic DNA, pick ~5 individuals and immobilize flies from the Cas9-expressing strain by placing them at 4°C for 5 min.

   c. Crush the flies with a pestle in an Eppendorf tube and follow the ‘Single fly DNA prep for PCR’ protocol found at [http://francois.schweisguth.free.fr/protocols/Single_fly_DNA_prep.pdf](http://francois.schweisguth.free.fr/protocols/Single_fly_DNA_prep.pdf).

   **Note:** If the gDNA quality is of insufficient purity or yield we recommend gDNA be extracted with the ChargeSwitch gDNA Micro Tissue Kit (Invitrogen), following the manufacturer’s protocol ([https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FLSG%2Fmanuals%2FchargeSwitch_gDNA_tissue.QRC.pdf](https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FLSG%2Fmanuals%2FchargeSwitch_gDNA_tissue.QRC.pdf)), We have observed gDNA extracted with this kit also provides a better template for amplification of larger DNA fragments (such as during the cloning of homology repair arms in steps 10 and 11 Repair Plasmid Cloning). As the gDNA kit is designed for tissues from larger organisms, half the recommended volume of buffers and solutions suffices.

   d. To PCR amplify the two regions containing the target sites from the gDNA, set up the following 50µL PCR reaction mix.

   | Reagent                          | Final concentration | Amount |
   |----------------------------------|---------------------|--------|
   | Q5 2X Master Mix                 | 1×                   | 25 µL  |
   | Forward Primer, 10 µM            | 0.5 µM              | 2.5 µL |
   | Reverse Primer, 10 µM            | 0.5 µM              | 2.5 µL |
   | gDNA                             | n/a                 | 2 µL   |
   | ddH2O                            | n/a                 | To 50 µL|

   e. Follow the PCR cycling conditions according to the protocol for Q5 2X Master Mix ([https://international.neb.com/protocols/2012/12/07/protocol-for-q5-high-fidelity-2x-master-mix-m0492](https://international.neb.com/protocols/2012/12/07/protocol-for-q5-high-fidelity-2x-master-mix-m0492)).
Note: The annealing temperature will depend on the primers used. Determine the suitable annealing temperature using NEB Tm calculator: https://tmcalculator.neb.com/

f. Run the PCR reaction mix in 1% agarose gel, purify the PCR product with the QIAquick Gel Extraction Kit, according to the manufacturer’s instructions (https://www.qiagen.com/gb/resources/resourcedetail?id=a72a2c07-7816-436f-b920-98a0ede5159a&lang=en).

g. Send the purified PCR product for sequencing and align the resulting sequence with the published sequence on FlyBase.

Note: If SNPs are present in either of the target sites, return to the previous section ‘sgRNA selection’ and choose alternative target site(s).
c. Design and order primers to PCR amplify the 3’ homology arm, including the chosen restriction sites at the 5’ ends of the primers to facilitate cloning into the pTVGFP vector (primers 5–6 in Figure 3C).

8. Design primers for insertion of the 5’ homology arm and the FRT cassette into multiple cloning site 1 (MCS1) using Gibson Assembly (NEB):
   a. Identify ~1000bp upstream of CRISPR-Cas9 target site number 1 (starting from the middle of the site. This will be the 5’ homology arm (Figure 2A).
   b. Select restriction sites that are only present in the MCS1, making sure the sites are not present in the 3’ arm (Figure 3A).
   c. Design and order primers to PCR amplify the 3’ homology arm, including a segment homologous to the linearized vector at the beginning of the forward primer (primers 1 and 2 in Figure 3B).
   d. Design and order primers to PCR amplify the region between the two target sites, nesting the FRT sequence within both the forward and the reverse primers (FRT71 sequence was used in the example of DWnt4[cKO]: GAAGTTCCTATTCTCTAGAAAGTATAG GAACCTT) (primers 3 and 4 in Figure 3B).

**Note:** Steps 7 and 8 can be swapped around, depending on the availability of unique restriction sites.

**Alternatives:** A more commonly used FRT sequence can be used instead (sequence: GAAGTTCCTATTCTCTAGAAAGTATAG GAACCTT). FRT71 was used in the DWnt4[cKO] example because this cKO was made in a background of another conditional allele that already contains FRT sites.
### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE         | IDENTIFIER     |
|---------------------|----------------|----------------|
| **Bacterial and virus strains**                               |                |                |
| DH5α competent cells  | Thermo Fisher  | Cat # 18265017 |
| **Chemicals, peptides, and recombinant proteins**             |                |                |
| Agarose             | Sigma-Aldrich  | Cat # 05066    |
| Protease K          | Thermo Fisher  | Cat # EO0491   |
| Tris-HCl            | Sigma-Aldrich  | Cat # 10812846001 |
| NaCl                | Sigma-Aldrich  | Cat # S9888    |
| EDTA                | Sigma-Aldrich  | Cat # E9884    |
| CutSmart buffer, 10× | NEB            | Cat # B7204    |
| Ampicillin          | Sigma-Aldrich  | Cat # A0166    |
| Yeast extract       | Oxoid          | Cat # LP0021   |
| Tryptone            | Oxoid          | Cat # LP0042   |
| Agar powder         | Sigma-Aldrich  | Cat # 05040    |
| Gibson Assembly Master Mix | NEB    | Cat # E2611    |
| Q5 High-Fidelity 2× master mix | NEB    | Cat # M0492    |
| T4 DNA ligase       | NEB            | Cat # M0202    |
| T4 DNA ligase reaction buffer | NEB  | Cat # B0202    |
| BbsI-HF             | NEB            | Cat # R3539    |
| **Critical commercial assays**                                |                |                |
| ChargeSwitch gDNA Micro Tissue Kit | Invitrogen  | Cat # CS11203  |
| QIAquick Gel Extraction Kit       | QIAGEN        | Cat # 28704    |
| QIAprep Spin Miniprep Kit         | QIAGEN        | Cat # 27104    |
| Invitrogen PureLink HiPure Plasmid Maxiprep Kit | Invitrogen  | Cat # K210006  |
| **Experimental models: Organisms/strains**                     |                |                |
| Drosophila melanogaster : yw,nos-Cas9(III-attP2) | (Kondo and Ueda, 2013) | N/A            |
| Drosophila melanogaster : w1118 | Crick Fly Facility | N/A            |
| **Oligonucleotides**                                           |                |                |
| FRT: GAAGTTCCTATTTCTAGAAAGTATAGGAACCTTC | N/A          | N/A            |
| FRT71 : GAAGTTCTATTCTCAGAATAGTTTCTATTC TCTAGAAGTATAGGAACCTTC | N/A          | N/A            |
| pCFD4 verification : GACACACGCGGCTACGTCTCTCG | N/A          | N/A            |
| pTVGF5 5’arm forward primer for verification: CAGTTCAGACGTGTTGAAACGA | N/A          | N/A            |
| pTVGF5 Pax reverse primer for verification: GAATATTAGCTTAAAAATTTGATGTCTCTCTTCAATTTGAATT | N/A          | N/A            |
| pTVGF5 3’arm forward primer for verification: GTTGGTGTGGTCTCCAAAACCTCAT | N/A          | N/A            |
| pTVGF5 3’arm reverse primer for verification: CCATGATTACGCCAAGC | N/A          | N/A            |
| **Recombinant DNA**                                            |                |                |
| pCFD4               | Port et al., 2014 | Addgene: 49411 |
| pCFD5               | (Port and Bullock, 2016) | Addgene: 73914 |
| pTVGF5             | (Yu et al., 2020)  | Addgene: 169445 |
| **Software and algorithms**                                   |                |                |
| UCSC Genome Browser  | (Kent et al., 2002) | https://genome.ucsc.edu/ |
| FlyBase             | n/a            | https://flybase.org |
| Serial Cloner       | n/a            | http://serialbasics.free.fr/Ser  ial_Cloner.html |
| Target Finder       | (Gratz et al., 2014)  | http://targetfinder.flycrispr.neuro.brown.edu/ |
MATERIALS AND EQUIPMENT

| Ampicillin LB plates                        | Final concentration | Amount |
|---------------------------------------------|---------------------|--------|
| Reagent                                     |                     |        |
| Yeast extract                               | n/a                 | 5 g    |
| Tryptone                                    | n/a                 | 10 g   |
| NaCl                                        | n/a                 | 10 g   |
| ddH₂O                                       | n/a                 | To 1 L |
| Ampicillin                                  | 100 µg/mL           | 0.1 g  |
| Agar powder                                 | n/a                 | 15 g   |
| Total                                       | n/a                 | 1 L    |

LB buffer is mixed with the 15 g of agar powder and is autoclaved at 121 °C for 15 min. Add Ampicillin after the solution is cooled to 55 °C. Pour the buffer into petri dishes and allow them to solidify. The Ampicillin LB plates can be stored at 4 °C for up to 2 months.

| Squishing buffer for single fly genomic DNA preparation | Final concentration |
|--------------------------------------------------------|---------------------|
| Reagent                                                |                     |
| Tris-HCL (pH=8.2)                                      | 10 mM               |
| EDTA                                                   | 1 mM                |
| NaCl                                                   | 25 mM               |
| ddH₂O                                                  | n/a                 |
| Proteinase K                                           | 200 µg/mL           |

Proteinase K should be added right before use. The squishing buffer can be stored at room temperature for up to one month.

STEP-BY-STEP METHOD DETAILS

sgRNA cloning

© Timing: 3–4 days

The protocol for cloning sgRNAs into the pCFD4 vector is according to (Port et al., 2014), which can be found at http://www.crisprflydesign.org/wp-content/uploads/2014/06/Cloning-with-pCFD4.pdf. The protocol for the alternative pCFD5 vector can be found at http://www.crisprflydesign.org/wp-content/uploads/2016/07/pCFD5cloningprotocol.pdf.

1. Using pCFD4 vector as a template, run a PCR with the primers from Before you begin step 6
   a. Set up the following PCR reaction mix

| Reagent                      | Final concentration | Amount |
|------------------------------|---------------------|--------|
| QS 2X Master Mix             | 1×                   | 25 µL  |
| Forward Primer, 10 µM        | 0.5 µM              | 2.5 µL |
| Reverse Primer, 10 µM        | 0.5 µM              | 2.5 µL |
| pCFD4 vector                 | n/a                 | 50 ng  |
| ddH₂O                        | n/a                 | To 50 µL |

b. Run the PCR by referring to the conditions from Before you begin step 5e. The optimal annealing temperature is 61 °C.

2. Digest pCFD4 vector with BbsI-HF at 37°C for 1 h, according to the following reaction mix.
3. Run PCR product and digested vector on 1% agarose gel.
   a. PCR product size: 600bp
   b. Digested vector size: 6.4 kb
4. Gel purify the PCR product and the digested vector with the QIAquick Gel Extraction Kit, according to the manufacturer’s instructions (https://www.qiagen.com/gb/resources/resourcedetail?id=a72e2c07-7816-436f-b920-98a0ede5159a&lang=en).
5. Insert the PCR product into the linearized vector using Gibson Assembly (NEB) according to the manufacturer’s instructions (https://international.neb.com/protocols/2012/12/11/gibson-assembly-protocol-e5510).
6. Transform with competent bacteria and plate on Ampicillin LB agar plates. The final concentration of Ampicillin is 100 $\mu$g/mL.
7. Pick a few individual colonies and culture 16 h for MiniPrep (Qiagen) the following day, following the manufacturer’s instructions (https://www.qiagen.com/us/resources/resourcedetail?id=331740ca-077f-4ddd-9e5a-2083f98eebd5&lang=en).
8. Verify insertion by sequencing with the following primer:
   a. Primer for verification: GACACAGCGCGTACGTCCTTCG
9. Purify the pCFD4 plasmid with a Maxiprep kit (Invitrogen) following the manufacturer’s instructions (https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FLSG%2Fmanuals%2Fpurelink_hipure_plasmid_qrc.pdf&title=UXVpY2sgUmVmZXJlbmNlOiBQdXJlTGluayBIaVB1cmUgUGxhc21pZCBETkEgUHVyaWZpY2F0aW9uIEdpdmUpHg=).

Pause point: the pCFD4 plasmid can be stored at –20°C for an extended period until injection.

**Repair plasmid cloning**

**Timing:** ~ 1 week

Components (5’ arm, region flanked by FRT sites, and 3’ arm) to be inserted into the parent repair vector pTV<sup>GFP</sup> are PCR amplified from genomic DNA extracted from the selected Cas9 line (Before you begin step 5).

10. Inserting 3’ homology arm into MCS2:
    a. PCR amplify the fragment using primers designed from Before you begin step 7c. Refer to Before you begin step 5d for PCR reaction mix, and Before you begin step 5e for PCR condition. Gel purify the PCR product (refer to Before you begin step 5f).
    b. Digest pTV<sup>GFP</sup> and the PCR product with the two restriction enzymes selected in Before you begin step 7b, setting up the following reaction mix for digesting the pTV<sup>GFP</sup> and the PCR product respectively. The reaction conditions required for the selected restriction enzymes can be found using the NEB Double Digest Finder (http://nebcloner.neb.com/).

Reaction mix for digesting pTV<sup>GFP</sup> backbone:

| Reagent       | Final concentration | Amount |
|---------------|---------------------|--------|
| pCFD4 vector  | n/a                 | 2 $\mu$g |
| CutSmart buffer, 10× | 1×                 | 1 $\mu$L |
| BbsI-HF       | n/a                 | 0.5 $\mu$L |
| ddH<sub>2</sub>O | n/a                 | to 10 $\mu$L |
Note: Other buffers may be required, depending on the restriction enzymes selected. Use NEB Double Digest Finder (http://nebcloner.neb.com/) to identify the suitable buffer.

Reaction mix for digesting the PCR product:

| Reagent               | Final concentration | Amount |
|-----------------------|---------------------|--------|
| pTV<sup>GFP</sup>     | n/a                 | 2 µg   |
| CutSmart buffer, 10×  | 1×                   | 1 µL   |
| Restriction enzyme 1  | n/a                 | 0.5 µL |
| Restriction enzyme 2  | n/a                 | 0.5 µL |
| ddH<sub>2</sub>O       | n/a                 | to 10 µL |

Note: Other buffers may be required, depending on the restriction enzymes selected. Use NEB Double Digest Finder (http://nebcloner.neb.com/) to identify the suitable buffer.

c. Ligate the digested pTV<sup>GFP</sup> backbone and the PCR product, following the manufacturer’s protocol for T4 DNA Ligase (NEB) for reaction mix and conditions (https://international.neb.com/protocols/0001/01/01/dna-ligation-with-t4-dna-ligase-m0202). This produces the pTV<sup>GFP</sup>-3’ arm vector.

d. Transform with competent bacteria and plate on Ampicillin plates.

e. Pick a few individual colonies and culture overnight for MiniPrep (Qiagen).

f. Verify insertion by sequencing with the following primers:
   i. pTV<sup>GFP</sup> 3’ arm forward primer for verification: GTTGTGGTTTTGTCAAAACAT
   ii. pTV<sup>GFP</sup> 3’ arm reverse primer for verification: CCAATGATTACGCCAGC

11. Inserting 5’ homology arm and FRT cassette into MCS1:

   a. PCR amplify the fragments using primers designed from Before you begin step 7c. Refer to Before you begin step 5d for PCR reaction mix, and Before you begin step 5e for PCR condition. Gel purify the PCR product (refer to Before you begin step 5f).

   b. Digest pTV<sup>GFP</sup>-3’ arm with the two restriction enzymes selected in Before you begin step 8b, referring to step 10b for reaction mix and condition.

   c. Assemble using Gibson assembly according to the manufacturer’s protocol (https://international.neb.com/protocols/2012/12/11/gibson-assembly-protocol-e5510), with the digested pTV<sup>GFP</sup>-3’ arm as the backbone and the two PCR products in step 10a as inserts. This generates the pTV<sup>FRT-GFP</sup> donor plasmid (see troubleshooting 3).

   d. Transform with competent bacteria and plate on Ampicillin plates.

   e. Pick a few individual colonies and culture overnight for MiniPrep (Qiagen).

   f. Verify insertion by sequencing with the following primers:
      i. pTV<sup>GFP</sup> 5’ arm forward primer for verification: CAGTCAACGGTGTAAAACGA
      ii. pTV<sup>GFP</sup> Pax reverse primer for verification: GAATTCAGCTCTAATTGAATTCAGCTCTAATT

Note: Steps 10 and 11 can be swapped around, depending on the availability of unique restriction sites
Instead of Gibson assembly, the components can be sequentially cloned into the repair vector using restriction sites from MCS1 via ligation (see troubleshooting 3).

12. Purify the pTV\textsuperscript{FRT-\textit{GFP}} plasmid with a Maxiprep kit (Invitrogen).

\*\* Pause point: the pTV\textsuperscript{FRT-\textit{GFP}} plasmid can be stored at \(-20^\circ\)C for an extended period until injection.

**Injection and screening**

\*\* Timing: \(~2\) weeks

The gRNA vector pCFD4 can be co-injected with the pTV\textsuperscript{FRT-\textit{GFP}} repair plasmid into embryos of any transgenic line that express Cas9 (Figure 4A). If in-house injection facilities are not available, the injection mix can be sent to companies for injection into commonly available Cas9 lines.

13. Expand the Cas9-expressing strain to be used for injection
14. The injection mix contains the pCFD4 and the pTV\textsuperscript{FRT-\textit{GFP}} plasmids in ddH\textsubscript{2}O.

\*\* Note: Plasmid concentrations can vary. Recommended concentrations are 100 ng/\(\mu\)L for pCFD4 and 500 ng/\(\mu\)L for pTV\textsuperscript{FRT-\textit{GFP}} for injecting into 300–400 embryos. Injection volume is typically less than 5% of the egg volume.
Note: Recommended amounts of each plasmid are 300 µg for pCFD4 and 500 µg for pTVFRT-GFP, for injecting into 300–400 embryos.

© Timing: 1–2 months

15. Injected embryos are grown to adulthood and crossed to w1118 flies. Screen for GFP signal in the next generation larval CNS or the adult eyes/ocelli (Figure 4A).

16. Select individual transformants and establish balanced GFP-positive transformant lines (see troubleshooting 4 and 5) (Figure 4A).

17. Extract gDNA from transformant lines and PCR verify the insertion is in the correct location. Design two sets of primers for the PCR verification, such that one of each set binds just outside the regions that correspond to the 5’ and 3’ arms, and the other binds to the GFP coding sequence (primers 1–4 in Figure 4B). For PCR reaction mixture and PCR conditions, refer to Before you begin steps 5d–e.

Optional: The pax-GFP flanked by loxP sites can be excised through Cre expression (Figure 4B). This can improve expression of the integrated fragment. Cre recombinase lines such as BL#766 and BL#851 from the Bloomington stock centre can be used.

Optional: Reintegration vectors can be introduced via the attP site via another round of injection. Examples include, introducing a GAL4 coding sequence into the locus, or reintroducing the CDS of the gene of interest but with a HA-tagged inserted within the CDS (Baena-Lopez et al., 2013, Poernbacher et al., 2019). (Figure 4C) Alternatively, instead of creating a conditional knockout, the re-integration vector can introduce another FRT cassette containing a mutant or tagged form of the gene of interest, thus generating a conditional switch allele. Details of the crossing scheme for the PhiC31-mediated reintegration can be found at (Hoppe and Ashe, 2021).

EXPECTED OUTCOMES
This protocol creates a conditional knockout allele of the gene of interest. In Yu et al., 2020, a conditional DWnt4 knockout allele was generated following this protocol. Tissue-specific gene inactivation (excision of the FRT-flanked DNA) was subsequently achieved by expressing a UAS-Flp transgene under the control of a wing-specific driver, thus creating a DWnt4 mutant wing in an otherwise wild type animal.

LIMITATIONS
Even though the FRT cassette, attP landing site and the selection markers are inserted into non-conserved regions of the genome, there is still a risk that reintegration of the rescue plasmid may not completely restore gene function. For essential genes, this can easily be assessed since the engineered flies would not be viable as homozygotes. Removal of the pax-GFP selection marker via Cre-expression could potentially solve the problem if the marker is affecting gene expression.

TROUBLESHOOTING
Problem 1
The target site search returned with no results on the CRISPR target finder tool, or only sites with multiple off-target sites (Before you begin step 4).

Potential solution
Try ‘Low Stringency’ instead, with the caveat that off-target events will be more likely.

The guide length can be reduced to 17–18nt, as it has been suggested that shorter gRNAs can decrease undesired off-target events without sacrificing on-target editing efficiency (Fu et al., 2014).
**Problem 2**
No unique restriction sites are present in MCS1 or MCS2 (Before you begin step 7).

**Potential solution**
Restriction enzymes that produce compatible cohesive or blunt ends could also be used. More information can be found at https://international.neb.com/tools-and-resources/selection-charts/compatible-cohesive-ends-and-generation-of-new-restriction-sites.

**Problem 3**
Gibson assembly of the 5’arm and FRT cassette into the parent repair plasmid was not successful, i.e., no colonies or getting a lot of background (Step-by-step Method step 11c)

**Potential solution**
Make sure the vector is digested properly, run an uncut plasmid in the gel electrophoresis along with the cut plasmid, they should migrate differently in the gel.

Instead of Gibson Assembly, the components can be sequentially cloned into the repair vector using restriction sites from MCS1 via ligation.

**Problem 4**
No GFP-positive candidates can be recovered from the progeny of injected individuals (Step-by-step Method step 16).

**Potential solution**
Double check there are no SNPs in the chosen target sites, specifically in the gDNA of the Cas9-expressing strains used for injection.

Cutting efficiency of sgRNAs can be predicted using the online tool at https://www.flyrnai.org/evaluateCrispr/.

Other ways of assessing cutting efficiency include testing in S2R+ cells and using a T7 endonuclease assay (Viswanatha et al., 2018).

Make sure the DNA plasmids for injection are good quality, for example, measure absorbance from 230 nm to 320 nm, the $A_{260}/A_{280}$ ratio should be around 1.7–2.0. If not, re-transform and Maxi-prep the plasmid. Briefly centrifuge the DNA plasmids at top speed for several minutes prior to injection.

Most commercial injection services inject around 200–300 embryos. For difficult or inaccessible CRISPR loci injecting more embryos may be required to increase the chances of obtaining a successful transformant.

Alternatively, choose new CRISPR target sites.

**Problem 5**
A range of pax-GFP signal intensities is seen in different candidate knockins (Step-by-step Method step 16).

**Potential solution**
Occasionally an extra pax-GFP cassette gets inserted in the genome, with commensurate increased GFP signal in the eyes. Establish stable strain from a single candidate that does not have a brighter than average GFP signal and confirm proper location by PCR sequencing.
RESOURCES AVAILABILITY

**Lead contact**
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jean-Paul Vincent (jpvincent@crick.ac.uk).

**Materials availability**
This study did not generate any unique reagents.

**Data and code availability**
This study did not generate any unique datasets or codes.

ACKNOWLEDGMENTS

We thank Filip Port for providing fly lines, Joachim Kurth (Crick Fly Facility) for Drosophila injections, and Cyrille Alexandre for advice on genome engineering. This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (no. FC001204), the UK Medical Research Council (no. FC001204), and the Wellcome Trust (no. FC001204). J.J.S.Y. was supported by the Francis Crick Ph.D. Training Programme.

AUTHOR CONTRIBUTIONS

The strategy was conceived by J.J.S.Y. and I.J.M. J.J.S.Y. executed all the experiments and wrote the first draft of the manuscript, which was subsequently edited by J.-P.V. and I.J.M.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

Baena-Lopez, L.A., Alexandre, C., Mitchell, A., Pasakarnis, L., and Vincent, J.P. (2013). Accelerated homologous recombination and subsequent genome modification in Drosophila. Development 140, 4818–4825.

Fu, Y., Sander, J.D., Reyon, D., Cacso, V.M., and Joung, J.K. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279–284.

Gratz, S.J., Ukken, F.P., Rubinstein, C.D., Thede, G., Donohue, L.K., Cummings, A.M., and O’Connor-Giles, K.M. (2014). Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila. Genetics 196, 961–971.

Hoppie, C., and Asher, H.L. (2021). CRISPR-Cas9 strategies to insert MS2 stem-loops into endogenous loci in Drosophila embryos. STAR Protocols 2, 100380.

Horn, C., Jaunich, B., and Wimmer, E.A. (2000). Highly sensitive, fluorescent transformation marker for Drosophila transgenesis. Dev. Genes Evol. 210, 623–629.

Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M., and Haussler, D. (2002). The human genome browser at UCSC. Genome Res. 12, 996–1006.

Kondo, S., and Ueda, R. (2013). Highly improved gene targeting by germline-specific Cas9 expression in Drosophila. Genetics 195, 715–721.

Poembacher, I., Crossman, S., Kurth, J., Nojima, H., Baena-Lopez, A., Alexandre, C., and Vincent, J.-P. (2019). Lessons in genome engineering: opportunities, tools and pitfalls. bioRxiv. https://doi.org/10.1101/710871.

Port, F., and Bullock, S.L. (2016). Augmenting CRISPR applications in Drosophila with tRNA-flanked sgRNAs. Nat. Methods 13, 852–854.

Port, F., Chen, H.M., Lee, T., and Bullock, S.L. (2014). Optimized CRISPR/Cas tools for efficient germline and somatic genome engineering in Drosophila. Proc. Natl. Acad. Sci. U S A 111, 2967–2976.

Viswanatha, R., Li, Z., Hu, Y., and Perrimon, N. (2018). Pooled genome-wide CRISPR screening for basal and context-specific fitness gene essentiality in Drosophila cells. Elife 7.

Yu, J.J.S., Maugarny-Cales, A., Pelletier, S., Alexandre, C., Bellache, Y., Vincent, J.P., and McGough, I.J. (2020). Frizzled-dependent planar cell polarity without secreted wnt ligands. Dev. Cell 54, 583–592.e5.